First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.

Hasan Mutlu,Hakan Bozcuk,Mehmet Artaç, İrfan Eser

Journal of cancer research and therapeutics（2023）

引用 0|浏览6

暂无评分

摘要

The usage of anti-PD1/PD-L1 immunotherapy agents results in significant OAS advantage, and anti-PD1/PD-L1 agents are superior to anti-CTLA-4 approach in combination with platinum plus etoposide regimen in ED-SCLC.

查看译文

关键词

lung cancer,meta-analysis meta-analysis,first-line,immune-checkpoint,extensive-disease,small-cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要